This study is looking at a condition called SARS-CoV-2 (COVID-19) infection in adults who are not in the hospital but are at high risk for becoming seriously ill from the infection. The treatment being tested is molnupiravir, also known by its code name MK-4482, which is given as tablets taken by mouth. Some people in the study will receive molnupiravir while others will receive placebo tablets that look the same but contain no active medicine. The purpose of the study is to find out if molnupiravir works to prevent serious outcomes from COVID-19 and to check if it is safe for people to use.
People taking part in this study must have tested positive for the virus that causes COVID-19 within four days before joining and must have symptoms like cough, sore throat, fever, muscle aches, or other common signs of the infection. They also need to have certain health conditions or characteristics that put them at higher risk for severe illness, such as being 75 years or older, having a weakened immune system, or having multiple health problems like diabetes or lung disease. Additionally, participants must be unable or unwilling to take another COVID-19 treatment called nirmatrelvir with ritonavir for various reasons, such as taking other medicines that would interact badly with it or having certain liver problems.
During the study, participants will take either molnupiravir or placebo tablets for five days, with a maximum daily dose of 1600 milligrams. The study will track whether participants need to go to the hospital, experience death, or need medical care related to COVID-19 over a period of 29 days. The study will also monitor how quickly symptoms improve, measure the amount of virus in the body over time, and watch for any unwanted side effects that occur during treatment. This information will help researchers understand whether molnupiravir is helpful and safe for people with COVID-19 who are at high risk for serious illness.
Bulgaria 
Finland 
France 
Germany 
Italy 
Poland 
Romania 
Spain 
